La-Z-Boy Inc (LZB)
$30.49 0.00 (0.00%)
19:00 EDT LZB Stock Quote Delayed 30 Minutes
Previous Close $30.49
Market Cap 1.42B
PE Ratio 18.26
Volume (Avg. Vol.)
Day's Range 30.49 - 30.49
52-Week Range 15.61 - 37.48
Dividend & Yield 0.48 (1.57%)
LZB Stock Predictions, Articles, and La-Z-Boy Inc News
- From InvestorPlace
- From the Web
The second part of 2020 will likely see growth in these three furniture stocks that are making work-from-home more comfortable.
La-Z-Boy (LZB) earnings for the furniture company's fiscal fourth quarter of 2020 have LZB stock on the move after markets closed on Tuesday.
La-Z-Boy (LZB) earnings for the company's fiscal second quarter of 2020 have LZB stock taking a beating after the markets closed Wednesday.
The stock charts of MKC, FMC and PFE are at major turning points here at the midpoint of the trading week.
La-Z-Boy earnings (LZB) were below what they were during the year-ago quarter, sending LZB stock sinking more than 9% after the bell today.
La-Z-Boy said that its earnings for its third quarter of fiscal 2019 tallied up to 63 cents per share, eight cents ahead of expectations.
La-Z-Boy earnings were stronger than what analysts were calling for, sending LZB stock soaring more than 10% after the bell on Wednesday.
If you are tired of hearing about the FANG's, you aren't alone, and you should check out this list of 20 top stocks that don't get the love they deserve.
La-Z-Boy Incorporated (LZB) posted its latest quarterly earnings results late Tuesday, which included an earnings beat and a revenue miss, sending shares down.
These 10 stocks to short could all be victims of a trade war with China. Here's the short case for each stock.
Five notable dividend stocks raised their payouts last week, including Disney (DIS) and McCormick (MKC). Here's what you need to know.
3 Stocks to Watch on Wednesday: Aclaris Therapeutics Inc (ACRS), Agilent Technologies Inc (A) and La-Z-Boy Incorporated (LZB)
Aclaris Therapeutics (ACRS) had a positive clinical trial, Agilent Technologies (A) reported earnings and La-Z-Boy (LZB) buys nine U.S. gallery stores.
I don't think much of the housing and real estate sectors in terms of stock market investments, and La-Z-Boy stock is no exception. Sell LZB
This week, the overall grades of 6 Household Durables stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Furniture maker Hooker missed on earnings in the latest quarter, and analysts are predicting similar results for FY 2016. Time to sell HOFT stock
The grades of 3 Household Durables stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.
Why La-Z-Boy Incorporated (LZB), Restoration Hardware Holdings Inc (RH) and SolarCity Corp (SCTY) Are 3 of Today’s Best Stocks
On a slow day for stocks, LZB, RH and SCTY soared and were easily three of the day's best performers.
Gainers: Arrowhead Pharmaceuticals (NASDAQ:ARWR) +47%.Eastman Kodak (NYSE:KODK) +39%.Myomo (NYSEMKT:MYO) +35%.Inovio Pharmaceuticals (NASDAQ:INO) +27%.Renren (NYSE:RENN) +25%.AMC Networks (NASDAQ:AMCX) +22%.Pacific Ethanol (NASDAQ:PEIX) +22%.Histogen (NASDAQ:HSTO) +21%.Heat Biologics (NASDAQ:HTBX) +16%.Ossen Innovation (NASDAQ:OSN) +16%.Losers: Novus Therapeutics (NASDAQ:NVUS) -17%.ADT (NYSE:ADT) -13%.American Axle & Manufacturing (NYSE:AXL) -12%.Forterra (NASDAQ:FRTA) -10%.8i Enterprises Acquisition (JFK) -10%.Francesca's (NASDAQ:FRAN) -10%.Grupo Supervielle (NYSE:SUPV) -9%.89bio (NASDAQ:ETNB) -9%.Jounce Therapeutics (NASDAQ:JNCE) -9%.Empresa Distribuidora (NYSE:EDN) -6%.
Arrowhead Pharmaceuticals, Myomo leads healthcare gainers, Novus Therapeutics, Jounce Therapeutics among major losers
Gainers: Arrowhead Pharmaceuticals (NASDAQ:ARWR) +46%, Myomo (NYSEMKT:MYO) +38%, AxoGen (NASDAQ:AXGN) +15%, Covetrus (NASDAQ:CVET) +14%, Inovio Pharmaceuticals (NASDAQ:INO) +13%.Losers: Novus Therapeutics (NASDAQ:NVUS) -13%, Jounce Therapeutics (NASDAQ:JNCE) -10%, Syneos Health (NASDAQ:SYNH) -7%, Verastem (NASDAQ:VSTM) -5%, Evogene (NASDAQ:EVGN) -5%.
Navellier RatingsPowered by Portfolio Grader